Currently, five HDAC inhibitors, namely Vorinostat, Belinostat, Romidepsin, Tucidinostat, and Panobinostat, have obtained approval for treating lymphoma and multiple myeloma. This evidence concerns the gene HDAC9 and lymphoma.